Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Prednisolone
Drug ID BADD_D01831
Description Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status approved; vet_approved
ATC Code A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID DB00860
KEGG ID D00472
MeSH ID D011239
PubChem ID 5755
TTD Drug ID D0D1SG
NDC Product Code 38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII 9PHQ9Y1OLM
Synonyms Prednisolone | Predate | Predonine | Di-Adreson-F | Di Adreson F | DiAdresonF
Chemical Information
Molecular Formula C21H28O5
CAS Registry Number 50-24-8
SMILES CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Chronic lymphocytic leukaemia01.10.06.001; 16.01.06.0010.000035%-
Chronic myeloid leukaemia01.10.07.001; 16.01.07.0010.000035%-
Circulatory collapse24.06.02.0010.000210%-
Clonus17.02.05.0020.000035%-
Coagulopathy01.01.02.0010.000122%-
Cold sweat08.01.03.024; 23.02.03.0020.000070%-
Colitis07.08.01.0010.000227%
Colitis ischaemic07.08.01.004; 24.04.08.0120.000140%-
Colitis ulcerative07.08.01.005; 10.02.01.0040.000367%-
Colon cancer07.21.01.001; 16.13.01.0010.000087%-
Condition aggravated08.01.03.0040.002635%-
Conjunctival oedema06.04.01.0010.000035%-
Conjunctivitis06.04.01.002; 11.01.06.012--
Coordination abnormal17.02.02.0040.000070%-
Corneal deposits06.06.03.0020.000140%-
Corneal epithelium defect06.06.03.0120.000087%-
Corneal lesion06.06.03.0040.000087%-
Corneal opacity06.06.03.0050.000087%-
Coronary artery thrombosis02.02.01.007; 24.01.05.0020.000035%-
Costochondritis15.07.03.0010.000052%-
Cranial nerve palsies multiple17.04.01.0030.000035%-
Crohn's disease07.08.01.015; 10.02.01.0050.000472%-
Cushing's syndrome05.01.01.001; 14.11.01.007; 19.07.03.002; 24.08.04.0010.000961%-
Cushingoid05.01.01.002; 14.11.01.006; 19.07.03.001; 24.08.02.0040.000748%
Cyanosis02.11.04.004; 22.02.02.007; 23.06.04.005; 24.03.01.0070.000070%
Deafness neurosensory04.02.01.002; 17.04.07.0010.000087%-
Decreased activity08.01.01.006; 19.11.01.0020.000087%-
Decreased immune responsiveness10.02.01.0410.000035%-
Delirium19.13.02.0010.000297%
Delusional disorder, unspecified type19.03.03.0020.000035%-
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene